Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories (NYSE: ABT) has reported Q1 adjusted earnings of $1.32 per share on $10.5 billion in sales for its first quarter. Though EPS was above the estimated $1.27, revenues fell short of the expectation of $10.69 billion.

Abbott Stock Is Trading Lower After Q1 Sales Shy Of Estimates

Abbott Laboratories (NYSE: ABT) reported its financial results for the fiscal first quarter on Tuesday that fell shy of the Wall Street estimates, despite its COVID-19 tests continuing to see strong demand in Q1. Abbott Laboratories shares that you can conveniently trade online via a range of user-friendly apps were reported more than 3% down […] The post Abbott Laboratories falls shy of Wall Street estimates in fiscal Q1 appeared first on Invezz.

Abbott Laboratories falls shy of Wall Street estimates in fiscal Q1

Shares of Abbott Laboratories were down 3.2% in premarket trading on Tuesday after the company beat earnings expectations during a quarter in which sales of its COVID-19 tests made up 20% of total revenue. Abbott had earnings of $1.8 billion, or $1.00 per share, in the first quarter of 2021, compared with $544 million, or 30 cents, in the same quarter a year ago.

Abbott's stock drops 3%, though earnings more than tripled for the medical test company in the first quarter

Shares of Abbott Laboratories (NYSE:ABT) moved higher by 0.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 103.08% over the past year to $1.32, which beat the estimate of $1.27.

Abbott Laboratories: Q1 Earnings Insights

Abbott Laboratories reported a more than threefold jump in quarterly profit on Tuesday, buoyed by robust demand for its COVID-19 test kits and growth in its diabetes and nutrition businesses.

Abbott first-quarter profit surges on COVID-19 test demand

Investors will be squarely focused on Abbott Laboratories results on Tuesday to assess the impact of swift vaccination rollout on demand for the company's COVID-19 tests.

Abbott's results a litmus test for COVID-19 testing demand

ABBOTT PARK, Ill., April 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.

Abbott Reports First-Quarter 2021 Results

On Tuesday, April 20, Abbott Laboratories (NYSE:ABT) will release its latest earnings report. Benzinga's outlook for Abbott Laboratories is included in the following report.

A Preview Of Abbott Laboratories's Earnings

ABBOTT PARK, Ill., April 19, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country.

Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today

Harley-Davidson

Steel Dynamics

United Continental Hlds

More than 300 publicly traded companies are expected to report March quarter earnings next week as earnings season revs up.

Earnings Previews: Abbott Labs, Harley-Davidson, Steel Dynamics, United Airlines

Abbott stock is scheduled to report its Q1 2021 results on Tuesday, April 20. We expect Abbott to report revenues in-line and earnings above the consensus estimates, driven by continued demand for Covid-19 testing, along with a rebound in demand for medical devices.

Here's Why We Think Abbott Stock Will Rise Post Q1

Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.

Demand for Nutrition Line to Drive Abbott (ABT) Q1 Earnings

Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.

Abbott (ABT) Gets Europe Nod for TriClip G4 to Treat TR

Accenture Plc

Colgate-Palmolive

Lowe's

Royal Bank of Canada

This article provides a summary of upcoming ex-dividend dates. We present a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: April 13-26, 2021

ABBOTT PARK, Ill., April 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it is teaming up with Eliud Kipchoge, who is considered the world's fastest marathon runner, and the NN Running Team to support their athletic performance training program.

World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games

Two elements will send revenue soaring in the coming months.

Why Abbott Labs Will Make You Richer in April (and Beyond!)

Abbott Laboratories (NYSE: ABT) won European approval for the latest generation of its TriClip system, a transcatheter-based repair device designed to stem leaks in the heart's tricuspid valve. The tricuspid valve opens and closes a set of three flaps rather than two.

Abbott's Upgraded TriClip Heart Valve System OK'd In Europe

Hormel Foods

Intuit

McCormick

Watsco

We provide a summary of upcoming ex-dividend dates. A summary table with relevant data and key statistics is presented. The table includes the next payout and pay date.

Upcoming Ex-Dividend Dates: April 9-19, 2021

ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip™ Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.

Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod

Abbott Labs is a healthcare conglomerate that has managed to grow despite restructuring its business over the past decade.

Abbott Labs: The Dividend Growth King Of Healthcare

Abbott Laboratories' (NYSE: ABT) XIENCE stent has received CE Mark in Europe for a shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients.

Abbott's XIENCE Stent Ok'd In Europe For Shorter Dual Anti-Platelet Therapy After Implant

ABBOTT PARK, Ill., April 6, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR).

Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients

According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.

Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use

Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.

News for Abbott Labs Stock (ABT)